carbamates and 4-amino-1-(3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1h)-one

carbamates has been researched along with 4-amino-1-(3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1h)-one in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cotler, SJ; Dahari, H; Guedj, J; Layden, TJ; Nettles, RE; Perelson, AS; Rong, L; Sansone, ND; Uprichard, SL1

Other Studies

1 other study(ies) available for carbamates and 4-amino-1-(3,4-dihydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1h)-one

ArticleYear
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Mar-05, Volume: 110, Issue:10

    Topics: Adult; Antiviral Agents; Bayes Theorem; Carbamates; Cell Line; Deoxycytidine; Female; Half-Life; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Middle Aged; Models, Biological; Pyrrolidines; RNA, Viral; Valine; Viral Load; Viral Nonstructural Proteins; Virus Assembly

2013